Evidence map›Paper›PMID 37715961›Full record

SynthesisStem cells translational medicine2023

Preclinical Evidence for the Use of Oral Mesenchymal Stem Cell-Derived Extracellular Vesicles in Bone Regenerative Therapy: A Systematic Review.

Allinson Olaechea, Karim Benabdellah, Andrea Vergara-Buenaventura, Sara Gómez-Melero, Emilio A Cafferata, Jonathan Meza-Mauricio, Miguel Padial-Molina, Pablo Galindo-Moreno

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Stem cells translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 3 countries.

Allinson OlaecheaDepartment of Oral Surgery and Implant Dentistry, School of Dentistry, University of Granada, Granada, Spain.ORCID 0000-0002-5907-9660
Karim BenabdellahDepartment of Genomic Medicine, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), Granada, Spain.
Andrea Vergara-BuenaventuraSchool of Dentistry, Universidad Científica del Sur, Lima, Perú.
Sara Gómez-MeleroMaimonides Biomedical research Institute of Cordoba (IMIBIC), Córdoba, Spain.
Emilio A CafferataSchool of Dentistry, Universidad Científica del Sur, Lima, Perú.
Jonathan Meza-MauricioSchool of Dentistry, Faculty of Health Sciences, Universidad Peruana de Ciencias Aplicadas, Lima, Perú.
Miguel Padial-MolinaDepartment of Oral Surgery and Implant Dentistry, School of Dentistry, University of Granada, Granada, Spain.
Pablo Galindo-MorenoDepartment of Oral Surgery and Implant Dentistry, School of Dentistry, University of Granada, Granada, Spain.
Universidad de Granada · ESGoethe University Frankfurt · DEInstituto Maimónides de Investigación Biomédica de Córdoba · ESPeruvian University of Applied Sciences · PEPfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research · ESUniversidad Científica del Sur · PE

Funding

Consejería de Salud y Familias, Junta de Andalucía ProyExcel_00875Consejería de Transformación Económica, Industria, Conocimiento y Universidades #CTS-1028Consejería de Transformación Económica, Industria, Conocimiento y Universidades, Junta de Andalucía, Spain #CTS-1028Junta de Andalucía, SpainUniversidad Peruana de Ciencias Aplicadas UPC-ExPost-2023-2
6 · The paper itself

Abstract

The development of extracellular vesicles (EVs) therapies has revolutionized personalized medicine, opening up new possibilities for treatment. EVs have emerged as a promising therapeutic tool within this field due to their crucial role in intercellular communication across various cell types and organisms. This systematic review aims to evaluate the therapeutic potential of oral mesenchymal stem cell (MSC)-derived EVs for bone regeneration, specifically focusing on findings from preclinical models. Sixteen articles meeting the inclusion criteria were selected following document analysis. The biological effects of oral MSC-derived EVs predominantly involve the upregulation of proteins associated with angiogenesis, and inflammation resolution, alongside the downregulation of proinflammatory cytokines. Moreover, these therapeutic agents have been found to contain a significant quantity of different molecules (proteins, lipids, DNA, microRNAs, etc) further contributing to their modulatory potential. The findings from this systematic review underscore that oral MSC-derived EVs, irrespective of their specific population, have the ability to enhance the osteogenic repair response in maxillary bone or periodontal defects. In summary, this systematic review highlights the promising potential of oral MSC-derived EVs for bone regeneration based on evidence from preclinical models. The comprehensive assessment of their biological effects and the presence of microRNAs underscores their therapeutic significance. These findings support the utilization of oral MSC-derived EVs in enhancing the osteogenic repair response in various maxillary bone or periodontal defects, providing insights into the mechanisms involved and potential therapeutic applications in the field of personalized medicine.

Indexed as

Extracellular VesiclesMesenchymal Stem CellsMicroRNAsBone RegenerationOsteogenesisMicroRNAsangiogenesisbone regenerationcellular therapyextracellular vesiclesoral mesenchymal stem cellsosteogenesispreclinical modelsproinflammatory cytokines

Identifiers

PMID37715961
PMCPMC10726404
OpenAlexW4386796361

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.